Hikma has the financial firepower and appetite to maintain its current deal-making momentum following several key transactions over the past year, CEO Siggi Olafsson tells Generics Bulletin in the first part of an exclusive interview, while also detailing how the firm plans to build up its US biosimilars business.
Hikma has the appetite to make more deals, according to CEO Siggi Olafsson, following a year that has seen it snap up major injectables assets and secure partnerships on US biosimilars.
Speaking to Generics Bulletin shortly after Hikma announced its 2021 results, Olafsson recapped some of the firm’s recent acquisitions and...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
